Farwell Wildon's Form 4 filing
Dyne Therapeutics, Inc. (DYN) · filed Dec 13, 2022
- Accession no.
- 0001209191-22-060969
- Filed
- Dec 13, 2022
- Trade date
- Dec 9-12, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.83K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farwell WildonCIK 0001847941 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock | AGrant or awardAcquired | +36,000 | $0.00 | $0 | 100,724 | Direct | |
| Dec 12, 2022 | Common Stock | SSaleDisposed | −628 | $10.87 | −$6,826.36 | 100,096 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock | AGrant or awardAcquired | +56,000 | $0.00 | $0 | 56,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.